Scarica l'app Stockscreener
3.37
6.65%
-0.24
Dopo l'orario di chiusura:
3.40
0.03
+0.89%
Poseida Therapeutics Inc Borsa (PSTX) Ultime notizie
How did Poseida Therapeutics Inc (PSTX) fare last session? - US Post News
Pivotree (CVE:PVT) Shares Up 3% - Defense World
Provident Financial Services And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™
Altrius Capital Management Inc Buys 15,174 Shares of POSCO Holdings Inc. (NYSE:PKX) - Defense World
Poseida Therapeutics Inc (PSTX) Stock: A Year of Market Fluctuations - The InvestChronicle
Piper Sandler maintains Overweight rating on Opko Health shares on strong prospects - Investing.com Canada
FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM - Myeloma Research News
FDA grants RMAT status to Poseida’s P-BCMA-ALLO1 for relapsed/refractory multiple myeloma - World Pharmaceutical Frontiers
FDA grants RMAT status to Poseida's multiple myeloma therapy By Investing.com - Investing.com Canada
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1 - Pharmaceutical Technology
FDA grants RMAT status to Poseida's multiple myeloma therapy - Investing.com
Portillos Inc (PTLO) receives an Overweight rating from Stephens - Knox Daily
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma - StockTitan
Acadian Asset Management LLC Buys 34,321 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump - Simply Wall St
Personalis (NASDAQ:PSNL) Stock Price Down 0.7% - Defense World
Poseida Therapeutics to Present at Upcoming Investor Conferences - Kilgore News Herald
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024 - Seeking Alpha
Poseida Therapeutics (NASDAQ:PSTX) Stock Price Down 2.5% - MarketBeat
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - BioSpace
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - Kilgore News Herald
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma - PR Newswire
Poseida Therapeutics to Present at Upcoming Investor Conferences - StockTitan
Poseida Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop - Simply Wall St
PSTX (Poseida Therapeutics) FCF Yield % : 0.07 (As of Aug. 19, 2024) - GuruFocus.com
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Purchase Of Investment : €-264.39 Mil (TTM As of Jun. 2024) - GuruFocus.com
PSTX (Poseida Therapeutics) Short-Term Debt & Capital Lease Obligation : $6.04 Mil (As of Jun. 2024) - GuruFocus.com
PSTX (Poseida Therapeutics) Long-Term Debt & Capital Lease Obligation : $77.61 Mil (As of Jun. 2024) - GuruFocus.com
PSTX (Poseida Therapeutics) Change In Prepaid Assets : $-0.70 Mil (TTM As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics (STU:2RZ) 3-Year FCF Growth Rate : 33.70% (As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Enterprise Value : €113.57 Mil (As of Aug. 19, 2024) - GuruFocus.com
Poseida Therapeutics (STU:2RZ) EPS (Diluted) : €-1.09 (TTM As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Cash, Cash Equivalents, Mark - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Shares Outstanding (Basic Av - GuruFocus.com
Poseida Therapeutics (STU:2RZ) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Cash-to-Debt : 2.84 (As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics (FRA:2RZ) Issuance of Stock : €13.51 Mil (TTM As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - Longview News-Journal
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Has $10.76 Million Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Short Interest Update - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Analysts Set Expectations for Poseida Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PSTX) - Defense World
William Blair Comments on Poseida Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PSTX) - Defense World
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Metric Deep Dive: Understanding Poseida Therapeutics Inc (PSTX) Through its Ratios - The Dwinnex
Poseida Therapeutics (NASDAQ:PSTX) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS - Defense World
Public Employees Retirement System of Ohio Grows Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics (NASDAQ:PSTX) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Poseida Therapeutics' (PSTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Receives Buy Rating from HC Wainwright - Defense World
Poseida Therapeutics Inc (PSTX) Q2 2024 Earnings: Revenue Surpas - GuruFocus.com
PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress - Morningstar
Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress - MarketWatch
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 - PR Newswire
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains - Yahoo Finance
Lazard Asset Management LLC Purchases 21,138 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Russell Investments Group Ltd. Makes New $110,000 Investment in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
10,200 Shares in Poseida Therapeutics, Inc. (NASDAQ:PSTX) Purchased by Bayesian Capital Management LP - Defense World
3.59%
5.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):